Please login to the form below

Not currently logged in
Email:
Password:

Wolters Kluwer drops pharma business

Healthcare information provider and consultancy, Wolters Kluwer, is to divest its pharmaceutical solutions business to focus on supporting other aspects of the healthcare market

Healthcare information provider and consultancy, Wolters Kluwer, is to divest its pharmaceutical solutions business to focus on supporting other aspects of the healthcare market.

Nancy McKinstry, CEO and chairman of the executive board of Wolters Kluwer, said: "The planned divestment of the pharma business will focus our health division on taking full advantage of our leading positions in professional information and clinical decision support solutions, one of the fastest growing areas of health, to deliver enhanced value to our stakeholders."

The company's pharmaceutical business currently includes products such as Source and Adis, with services providing support in development, marketing and distribution. This is made in available through textbooks and journals, electronic drug data, clinical information, and other evidence-based content.

The divestiture is expected to close around the end of the 2011.

27th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics